secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2024-08-12T23:59:59+00:00
Accession:  0001104659-24-088108
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed prices $75M public offering of common shares and pre-funded warrants; cash position $243.1M
--------------------------------------------------------------------------------

- Underwritten public offering of 9,285,511 common shares at $7.00/share and 1,428,775 pre-funded warrants at $6.999/warrant.
- Gross proceeds of ~$75M; net proceeds of ~$70M after underwriting discounts and expenses.
- Preliminary cash and cash equivalents of ~$243.1M as of June 30, 2024, disclosed in prospectus supplement.
- Offering expected to close on August 12, 2024; net proceeds to fund R&D and working capital.
- Leerink Partners and Evercore ISI acting as joint bookrunning managers; RBC and Oppenheimer as lead managers.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000110465924088108/0001104659-24-088108-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000110465924088108/tm2420790d4_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-088108

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer